Minister of Chemical substances and Fertilisers DV Sadanand Gowda on Wednesday mentioned the Division of Prescription drugs has given its nod for lifting of ban on the export of anti-malarial drug hydroxychloroquine API in addition to its formulations.
“Producers besides SEZ/EOU Items have to produce 20 per cent manufacturing within the home market. DGFT has been requested to situation a proper notification on this regard,” he mentioned on Twitter.
India had banned export of hydroxychloroquine on March 25, with some exceptions, amid views in some quarters that the drug could possibly be used to struggle COVID-19. On April four, it fully banned the exports with none exception.
The Directorate Basic of International Commerce (DGFT) has been requested to situation formal notification on this regard, the minister added.
In one other tweet, Gowda mentioned he held discussions with representatives of pharma firms together with a few of his ministerial colleagues on the challenges being confronted by the business and on the roadmap to spice up exports.
“Had detailed dialogue with representatives of pharma firms & affiliation, stakeholder Ministries together with Hon Ministers @piyushGoyal ji, @HardeepSPuri ji, & @MansukhMandviya ji on total gamut of challenges confronted by the business in addition to methods to spice up pharma export,” Gowda tweeted.
India exported hydroxychloroquine API (energetic pharmaceutical ingredient) price USD 1.22 billion in April-January 2019-20.
Throughout the identical interval, exports of formulations produced from hydroxycholoroquine was at USD 5.50 billion.
Read More Business News Here.
News Source